home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
  HUM-MOLGEN -> Genetic News | search  
 

Understanding A Side Effect Of TZDs

 
  July, 12 2005 11:05
your information resource in human molecular genetics
 
     
Thiazolidinediones (TZDs) are widely used to treat type-2 diabetes, but their use is complicated by systemic fluid retention. A paper in the August 2005 issue of Nature Medicine discloses the mechanism underlying this side effect.

In the kidney, the pharmacological target of TZDs, peroxisome proliferator-activated receptor-gamma (PPARg), is most abundant in the collecting duct of the nephron --the filtering unit of the kidney. Matthew Breyer and colleagues show that mice treated with TZDs retain water, an effect that was blocked by selective deletion of PPARg from the collecting duct. Deletion of PPARg decreased the transport of sodium through the sodium-selective channel Enac-g.

This study identifies Enac-g as a PPARg target in the collecting duct, suggesting that selective blockers of this channel might provide a specific therapy against fluid retention, an undesirable side effect of TZDs.

Author contact:

Matthew Breyer (Vanderbilt University, Nashville, TN, USA)
E-mail: matthew.breyer@vanderbilt.edu

Also published online.

(C) Nature Medicine press release.


Message posted by: Trevor M. D'Souza

print this article mail this article
Bookmark and Share this page (what is this?)

Social bookmarking allows users to save and categorise a personal collection of bookmarks and share them with others. This is different to using your own browser bookmarks which are available using the menus within your web browser.

Use the links below to share this article on the social bookmarking site of your choice.

Read more about social bookmarking at Wikipedia - Social Bookmarking

Latest News
Variants Associated with Pediatric Allergic Disorder

Mutations in PHF6 Found in T-Cell Leukemia

Genetic Risk Variant for Urinary Bladder Cancer

Antibody Has Therapeutic Effect on Mice with ALS

Regulating P53 Activity in Cancer Cells

Anti-RNA Therapy Counters Breast Cancer Spread

Mitochondrial DNA Diversity

The Power of RNA Sequencing

‘Pro-Ageing' Therapy for Cancer?

Niche Genetics Influence Leukaemia

Molecular Biology: Clinical Promise for RNA Interference

Chemoprevention Cocktail for Colon Cancer

more news ...

Generated by News Editor 2.0 by Kai Garlipp
WWW: Kai Garlipp, Frank S. Zollmann.
7.0 © 1995-2016 HUM-MOLGEN. All rights reserved. Liability, Copyright and Imprint.